Abstract Background Patients with cancer of the oesophagus or gastro-oesophageal junction have a high risk of recurrence after treatment with curative intent. The aim of this study was to analyse the site of recurrence, treatment, and survival in patients with recurrent disease. Methods Patients with non-metastatic oesophageal or junctional carcinoma treated with curative intent between January 2015 and December 2016 were selected from the Netherlands Cancer Registry. Data on recurrence were collected in the second half of 2019. Overall survival (OS) was assessed by Kaplan–Meier methods. Results In total, 862 of 1909 patients (45.2 per cent) for whom information on follow-up was available had disease recurrence, and 858 patients were included. Some 161 of 858 patients (18.8 per cent) had locoregional recurrence only, 415 (48.4 per cent) had distant recurrence only, and 282 (32.9 per cent) had combined locoregional and distant recurrence. In all, 518 of 858 patients (60.4 per cent) received best supportive care only and 315 (39.6 per cent) underwent tumour-directed therapy. Patients with locoregional recurrence alone more often received chemoradiotherapy than those with distant or combined locoregional and distant recurrence (19.3 per cent versus 0.7 and 2.8 per cent), and less often received systemic therapy (11.2 per cent versus 30.1 and 35.8 per cent). Median OS was 7.6, 4.2, and 3.3 months for patients with locoregional, distant, and combined locoregional and distant recurrence respectively (P < 0.001). Conclusion Disease recurred after curative treatment in 45.2 per cent of patients. Locoregional recurrence developed in only 18.8 per cent. The vast majority of patients presented with distant or combined locoregional and distant recurrence, and received best supportive care.

中文翻译：

---

基于人群的复发性食管癌或交界癌的治疗和结果研究

摘要 背景食管癌或胃食管交界处癌症患者在根治性治疗后复发的风险很高。本研究的目的是分析复发性疾病患者的复发部位、治疗和生存情况。 方法2015 年 1 月至 2016 年 12 月期间接受根治性治疗的非转移性食管癌或交界癌患者选自荷兰癌症登记处。2019 年下半年收集了复发数据。通过 Kaplan-Meier 方法评估总生存期 (OS)。 结果总共有 1909 名可获得随访信息的患者中，有 862 名患者（45.2%）出现疾病复发，其中包括 858 名患者。858 名患者中约有 161 名（18.8%）仅出现局部复发，415 名（48.4%）仅出现远处复发，282 名（32.9%）出现局部和远处复发。总共，858 名患者中的 518 名（60.4%）仅接受了最佳支持治疗，315 名（39.6%）接受了肿瘤定向治疗。单独局部区域复发的患者比远处或联合局部区域和远处复发的患者更常接受放化疗（19.3%对0.7%和2.8%），并且较少接受全身治疗（11.2%对30.1%和35.8%）。局部区域复发、远处复发以及局部区域和远处联合复发患者的中位 OS 分别为 7.6、4.2 和 3.3 个月（P < 0.001）。 结论45.2%的患者在治愈后疾病复发。局部复发率仅为 18.8%。绝大多数患者出现远处或局部区域和远处联合复发，并接受了最佳支持治疗。